文献速递淋巴瘤造血干细胞移植与细胞治疗

输注时达完全缓解的弥漫大B细胞淋巴瘤患者CAR-T细胞稳健扩增且结局更优

Robust CAR T-cell expansion and superior outcomes in DLBCL patients in complete response at infusion.
PubMed 文献 · Br J Haematol · 2025-05-25

该单中心回顾性分析纳入87例接受CAR-T治疗的复发/难治性弥漫大B细胞淋巴瘤患者,其中输注前完全缓解(CR)23例(26.4%)、非CR 64例(73.6%)。CR组无进展生存期和总生存期均显著优于非CR组,而外周血CAR-T细胞扩增与持续性在两组间无显著差异。

要点

  • 输注前达CR的复发/难治性弥漫大B细胞淋巴瘤患者CAR-T治疗后PFS和OS显著优于非CR患者。
  • CR与非CR患者外周血CAR-T细胞比例及绝对计数均无显著差异。
  • 4-1BB或CD28为基础的不同CAR-T产品中上述结果一致。

核心结论

  • CAR-T细胞治疗在输注前达CR的弥漫大B细胞淋巴瘤患者中仍可实现稳健扩增并获得良好生存结局,即使缺乏可测量病灶。

研究设计与样本

  • 单中心回顾性分析,纳入87例接受CAR-T治疗的复发/难治性弥漫大B细胞淋巴瘤患者。

主要发现

  • 输注前CR患者23例(26.4%),非CR患者64例(73.6%)。
  • CR组无进展生存期和总生存期均显著优于非CR组。
  • 外周血CAR-T细胞、CD4+ CAR-T细胞和CD8+ CAR-T细胞的比例及绝对计数在CR与非CR组间均无显著差异。
  • 上述结果在4-1BB为基础和CD28为基础的CAR-T产品中一致。
  • PET-CT达完全代谢缓解(CMR)与未达CMR患者CAR-T细胞扩增和持续性相当。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Historically, the presence of measurable disease has been considered essential to stimulate CAR T-cell expansion and persistence. However, the kinetics of CAR T cells in patients achieving complete response (CR) before infusion remain poorly understood. This study aimed to evaluate the outcomes and CAR T-cell kinetics in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients stratified by pre-infusion disease status. In this retrospective analysis of 87 patients treated at a single institution, 23 (26.4%) were in CR and 64 (73.6%) were in non-CR prior to CAR T-cell infusion. Patients in CR exhibited significantly better progression-free survival (PFS) and overall survival compared to non-CR patients. Peripheral blood CAR T-cell kinetics, including the proportion and absolute counts of CAR T cells, CD4+ CAR T cells and CD8+ CART cells, showed no significant differences between CR and non-CR groups. These findings were consistent across different CAR T-cell products, whether 4-1BB- or CD28-based. Moreover, an analysis of patients achieving complete metabolic response (CMR) by PET-CT confirmed comparable CAR T-cell expansion and persistence in both CMR and non-CMR patients. Our findings demonstrate that CAR T-cell therapy achieves robust expansion and favourable survival outcomes in CR patients, even in the absence of measurable disease.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Hanajiri R, Wakabayashi H, Ishigiwa K, et al. Robust CAR T-cell expansion and superior outcomes in DLBCL patients in complete response at infusion. Br J Haematol. 2025. PMID: 40415166. doi:10.1111/bjh.20186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。